Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease

Braak, 2000, Pathoanatomy of Parkinson's disease, J. Neurol., 247, II3 Cannon, 2010, Neurotoxic in vivo models of Parkinson's disease recent advances, Prog. Brain Res., 184, 17, 10.1016/S0079-6123(10)84002-6 Cenci, 1992, Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum, Neuroscience, 46, 943, 10.1016/0306-4522(92)90196-9 Cheng, 2010, Clinical progression in Parkinson disease and the neurobiology of axons, Ann. Neurol., 67, 715, 10.1002/ana.21995 Chung, 2009, Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy, J. Neurosci. Off. J. Soc. Neurosci., 29, 3365, 10.1523/JNEUROSCI.5427-08.2009 Cooper, 2006, Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models, Science, 313, 324, 10.1126/science.1129462 Decressac, 2011, GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease, Brain J. Neurol., 134, 2302, 10.1093/brain/awr149 Decressac, 2012, Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons, Neurobiol Dis., 45, 939, 10.1016/j.nbd.2011.12.013 Dowd, 2005, The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum, Brain Res. Bull., 68, 24, 10.1016/j.brainresbull.2005.08.009 Ebrahimi-Fakhari, 2011, Distinct roles in vivo for the ubiquitin–proteasome system and the autophagy–lysosomal pathway in the degradation of {alpha}-synuclein, J. Neurosci. Off. J. Soc. Neurosci., 31, 14508, 10.1523/JNEUROSCI.1560-11.2011 Grealish, 2010, The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease, Brain J. Neurol., 133, 482, 10.1093/brain/awp328 Grimm, 2002, Production methods for gene transfer vectors based on adeno-associated virus serotypes, Methods, 28, 146, 10.1016/S1046-2023(02)00219-0 Kirik, 1998, Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat, Exp. Neurol., 152, 259, 10.1006/exnr.1998.6848 Kirik, 2001, Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease, Eur. J. Neurosci., 13, 1589, 10.1046/j.0953-816x.2001.01534.x Kirik, 2002, Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system, J. Neurosci., 22, 2780, 10.1523/JNEUROSCI.22-07-02780.2002 Klein, 2002, Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra, Hum. Gene Ther., 13, 605, 10.1089/10430340252837206 Lo Bianco, 2002, alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease, Proc. Natl. Acad. Sci. U. S. A., 99, 10813, 10.1073/pnas.152339799 Lundblad, 2012, Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons, Proc Natl Acad Sci U S A, 109, 3213, 10.1073/pnas.1200575109 Magen, 2010, Genetic mouse models of Parkinson's disease. The state of the art, Prog. Brain Res., 184, 53, 10.1016/S0079-6123(10)84004-X Meissner, 2011, Priorities in Parkinson's disease research, Nat. Rev. Drug Discov., 10, 377, 10.1038/nrd3430 Paxinos, 1986 Rosenblad, 2000, Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model, Exp. Neurol., 161, 503, 10.1006/exnr.1999.7296 Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Torres, 2008, Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease, Neuroscience, 154, 631, 10.1016/j.neuroscience.2008.03.048 Torres, 2011, Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates, J. Neurosci. Methods, 200, 29, 10.1016/j.jneumeth.2011.06.012 Ulusoy, 2010, Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease, Prog. Brain Res., 184, 89, 10.1016/S0079-6123(10)84005-1 Ungerstedt, 1970, Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system, Brain Res., 24, 485, 10.1016/0006-8993(70)90187-3 Venda, 2010, alpha-Synuclein and dopamine at the crossroads of Parkinson's disease, Trends Neurosci., 33, 559, 10.1016/j.tins.2010.09.004 Winkler, 2000, Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement, Prog. Brain Res., 127, 233, 10.1016/S0079-6123(00)27012-X Yamada, 2004, Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease, J. Neurochem., 91, 451, 10.1111/j.1471-4159.2004.02728.x Zolotukhin, 1999, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther., 6, 973, 10.1038/sj.gt.3300938